{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T03:15:52Z","timestamp":1771125352788,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM63674"],"award-info":[{"award-number":["R01-GM63674"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DA14211"],"award-info":[{"award-number":["R01-DA14211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24-DA00417"],"award-info":[{"award-number":["K24-DA00417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40262-024-01406-y","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:01:31Z","timestamp":1722225691000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-922X","authenticated-orcid":false,"given":"Evan D.","family":"Kharasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Bedynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"1406_CR1","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3390\/biomedicines10112686","volume":"10","author":"LS Klyushova","year":"2022","unstructured":"Klyushova LS, Perepechaeva ML, Grishanova AY. The role of CYP3A in health and disease. Biomedicines. 2022;10:2686.","journal-title":"Biomedicines."},{"key":"1406_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bcpt.13780","volume":"131","author":"DB Iversen","year":"2022","unstructured":"Iversen DB, Andersen NE, Dalg\u00e5rd Dunvald AC, Potteg\u00e5rd A, Stage TB. Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin Pharmacol Toxicol. 2022;131:311\u201324.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1406_CR3","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","volume":"94","author":"J Hakkola","year":"2020","unstructured":"Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020;94:3671\u2013722.","journal-title":"Arch Toxicol"},{"key":"1406_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/dmd.121.000401","volume":"50","author":"J Yu","year":"2022","unstructured":"Yu J, Wang Y, Ragueneau-Majlessi I. Pharmacokinetic drug-drug interactions with drugs approved by the US Food and Drug Administration in 2020: mechanistic understanding and clinical recommendations. Drug Metab Dispos. 2022;50:1\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1406_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/cpt.1349","volume":"105","author":"RH Levy","year":"2019","unstructured":"Levy RH, Ragueneau-Majlessi I. Past, present, and future of drug-drug interactions. Clin Pharmacol Ther. 2019;105:1286\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cpt.1984","volume":"109","author":"X Yang","year":"2021","unstructured":"Yang X, Pfuma Fletcher E, Huang SM, Zineh I, Madabushi R. Regulatory efforts to facilitate evaluation and clinical management of drug-drug interaction risks. Clin Pharmacol Ther. 2021;109:42\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/cts.13172","volume":"15","author":"EJ Cox","year":"2022","unstructured":"Cox EJ, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF. Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: a NaPDI Center recommended approach. Clin Transl Sci. 2022;15:322\u20139.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1406_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sj\u00f6stedt N, Aleksunes L, et al. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov. 2024;23(4):255\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"1406_CR9","unstructured":"Food and Drug Administration. Clinical drug interaction studies- Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2020 https:\/\/www.fda.gov\/media\/134581\/download."},{"key":"1406_CR10","unstructured":"International Council for Harmonisation. ICH Guideline M12 on drug interaction studies - Scientific guideline. 2022 www.ema.europa.eu\/en\/ich-m12-drug-interaction-studies-scientific-guideline."},{"key":"1406_CR11","unstructured":"Ministry of Labor and Welfare (Japan). Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information, Notification No.0723-4, Pharmaceutical Evaluation Division, Pharmaceuticals Safety and Environmental Health Bureau, Japan. Ministry of Labor and Welfare; 2018. 2018 www.pmda.go.jp\/files\/000228122.pdf."},{"key":"1406_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3188","author":"R Viviani","year":"2024","unstructured":"Viviani R, Berres J, Stingl JC. Phenotypic models of drug-drug-gene interactions mediated by cytochrome drug-metabolizing enzymes. Clin Pharmacol Ther. 2024. https:\/\/doi.org\/10.1002\/cpt.3188.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR13","first-page":"577","volume":"67","author":"PB Watkins","year":"2000","unstructured":"Watkins PB. Erythromycin breath test. Clin Pharmacol Ther. 2000;67:577\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1248\/cpb.c14-00250","volume":"62","author":"H Mitome","year":"2014","unstructured":"Mitome H, Sugiyama E, Sato H, Akira K. Synthesis of 13C-lidocaine as a probe of breath test for the evaluation of cytochrome P450 activity. Chem Pharm Bull (Tokyo). 2014;62:806\u20139.","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"1406_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach. Clin Pharmacol Ther. 2007;81:270\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","volume":"12","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016;12:479\u201397.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1406_CR17","first-page":"549","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther. 1994;271:549\u201356.","journal-title":"J Pharmacol Exp Ther"},{"key":"1406_CR18","first-page":"557","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability following liver transplantation. J Pharmacol Exp Ther. 1994;271:557\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"1406_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1124\/dmd.110.032094","volume":"38","author":"RS Foti","year":"2010","unstructured":"Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010;38:981\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1406_CR20","unstructured":"Food and Drug Administration. Guidance for industry: Drug interaction studies- study design, data analysis, implications for dosing, and labeling recommendations. 2012 https:\/\/www.regulations.gov\/document\/FDA-2006-D-0036-2."},{"key":"1406_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","volume":"76","author":"ED Kharasch","year":"2004","unstructured":"Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment using pupillary miosis. Clin Pharmacol Ther. 2004;76:452\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1177\/0091270005280077","volume":"45","author":"ED Kharasch","year":"2005","unstructured":"Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol. 2005;45:1187\u201397.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","volume":"82","author":"ED Kharasch","year":"2007","unstructured":"Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007;82:410\u201326.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00003088-200746030-00006","volume":"46","author":"N Baririan","year":"2007","unstructured":"Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq P, Starkel P, et al. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet. 2007;46:261\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"1406_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1471-2288-13-100","volume":"13","author":"Y Guo","year":"2013","unstructured":"Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with repeated measures. BMC Med Res Methodol. 2013;13:100.","journal-title":"BMC Med Res Methodol"},{"key":"1406_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00000542-199707000-00005","volume":"87","author":"ED Kharasch","year":"1997","unstructured":"Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology. 1997;87:26\u201335.","journal-title":"Anesthesiology"},{"key":"1406_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/00912709922008290","volume":"39","author":"ED Kharasch","year":"1999","unstructured":"Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KT. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol. 1999;39:664\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1067\/mcp.2003.30","volume":"73","author":"ED Kharasch","year":"2003","unstructured":"Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther. 2003;73:199\u2013208.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","volume":"74","author":"JC Gorski","year":"2003","unstructured":"Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275\u201387.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clpt.2005.08.004","volume":"78","author":"HN Chaobal","year":"2005","unstructured":"Chaobal HN, Kharasch ED. Single point sampling for assessment of constitutive, induced and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther. 2005;78:529\u201339.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/clpt.2011.59","volume":"90","author":"ED Kharasch","year":"2011","unstructured":"Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011;90:100\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219854","volume":"14","author":"D Liljequist","year":"2019","unstructured":"Liljequist D, Elfving B, Skavberg RK. Intraclass correlation\u2014a discussion and demonstration of basic features. PLoS\u00a0One. 2019;14: e0219854.","journal-title":"PLoS\u00a0One"},{"key":"1406_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/psp4.12007","volume":"4","author":"A van Rongen","year":"2015","unstructured":"van Rongen A, Kervezee L, Brill M, van Meir H, den Hartigh J, Guchelaar HJ, et al. Population pharmacokinetic model characterizing 24-hour variation in the pharmacokinetics of oral and intravenous midazolam in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2015;4:454\u201364.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1406_CR34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1124\/dmd.122.001066","volume":"51","author":"KD Jackson","year":"2023","unstructured":"Jackson KD, Achour B, Lee J, Geffert RM, Beers JL, Latham BD. Novel approaches to characterize individual drug metabolism and advance precision medicine. Drug Metab Dispos. 2023;51:1238\u201353.","journal-title":"Drug Metab Dispos"},{"key":"1406_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/009127009903900311","volume":"39","author":"ED Kharasch","year":"1999","unstructured":"Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol. 1999;39:275\u201380.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0009-9236(98)90175-8","volume":"64","author":"ADM Kashuba","year":"1998","unstructured":"Kashuba ADM, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther. 1998;64:269\u201377.","journal-title":"Clin Pharmacol Ther"},{"key":"1406_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40262-023-01257-z","volume":"62","author":"KE Kvitne","year":"2023","unstructured":"Kvitne KE, Drevland OM, Haugli N, Skadberg E, Zar\u00e9 HK, \u00c5sberg A, et al. Intraindividual variability in absolute bioavailability and clearance of midazolam in healthy individuals. Clin Pharmacokinet. 2023;62:981\u20137.","journal-title":"Clin Pharmacokinet"},{"key":"1406_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/dmd.112.048561","volume":"41","author":"H Shibasaki","year":"2013","unstructured":"Shibasaki H, Hosoda K, Goto M, Suzuki A, Yokokawa A, Ishii K, et al. Intraindividual and interindividual variabilities in endogenous cortisol 6\u00df-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. Drug Metab Dispos. 2013;41:475\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1406_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","volume":"10","author":"V \u00d6zdemir","year":"2000","unstructured":"\u00d6zdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373\u201388.","journal-title":"Pharmacogenetics"},{"key":"1406_CR40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","volume":"11","author":"YS Lin","year":"2001","unstructured":"Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001;11:781\u201391.","journal-title":"Pharmacogenetics"},{"key":"1406_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/00912700222011418","volume":"42","author":"JS Kim","year":"2002","unstructured":"Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002;42:376\u201382.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0091270005283466","volume":"46","author":"LS Lee","year":"2006","unstructured":"Lee LS, Bertino JS Jr, Nafziger AN. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol. 2006;46:229\u201334.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.5414\/CP201701","volume":"50","author":"AN Nguyen","year":"2012","unstructured":"Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma JD. Evaluation of intravenous midazolam limited sampling models to determine area unde6r the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2012;50:468\u201375.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1406_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bcpt.12492","volume":"118","author":"SJ Woolsey","year":"2016","unstructured":"Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, et al. Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral midazolam microdose phenotype in healthy subjects. Basic Clin Pharmacol Toxicol. 2016;118:284\u201391.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1406_CR45","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/jcph.1125","volume":"58","author":"J Yang","year":"2018","unstructured":"Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, et al. Midazolam single time point concentrations to estimate exposure and cytochrome P450 (CYP) 3A constitutive activity utilizing limited sampling strategy with a population pharmacokinetic approach. J Clin Pharmacol. 2018;58:1205\u201313.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR46","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/jcph.1440","volume":"59","author":"J Yang","year":"2019","unstructured":"Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, et al. Midazolam limited sampling strategy with a population pharmacokinetic approach to simultaneously estimate cytochrome P450 (CYP) 3A constitutive, inhibition, and induction\/activation conditions in healthy adults. J Clin Pharmacol. 2019;59:1495\u2013504.","journal-title":"J Clin Pharmacol"},{"key":"1406_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.5414\/CPP48847","volume":"48","author":"JD Ma","year":"2010","unstructured":"Ma JD, Nguyen ET, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, et al. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2010;48:847\u201353.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1406_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00228-012-1437-9","volume":"69","author":"SC Mueller","year":"2013","unstructured":"Mueller SC, Drewelow B. Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies. Eur J Clin Pharmacol. 2013;69:1127\u201334.","journal-title":"Eur J Clin Pharmacol"},{"key":"1406_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00007256-200333030-00005","volume":"33","author":"P Thirup","year":"2003","unstructured":"Thirup P. Haematocrit: within-subject and seasonal variation. Sports Med. 2003;33:231\u201343.","journal-title":"Sports Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01406-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:19:10Z","timestamp":1724455150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01406-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01406-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"16 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supported by NIH grants R01-GM63674, R01-DA14211, and K24-DA00417 (EDK), and by M01-RR00037, provided to the University of Washington General Clinical Research Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Evan D. Kharasch, Christine Hoffer, and Pamela Bedynek declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study conception and design and supervision: EDK. Data collection and patient management: CH. Analytical: PB. Data analysis: EDK. Manuscript writing, revision, and approval: EDK, CH, PB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The study protocol was approved by the University of Washington Institutional Review Board Ethics Committee, approval number HSRC 004540A01.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written, informed consent was obtained from all trial participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}